Cited by 35Cancer, Hypoxia, and MetabolismRenal cell carcinoma treatmentVitamin C and Antioxidants Research

The Association Between Ascorbate and the Hypoxia-Inducible Factors in Human Renal Cell Carcinoma Requires a Functional Von Hippel-Lindau Protein

Open access
Wohlrab, Christina, Vissers, Margreet C. M., Phillips, Elisabeth, Morrin, Helen, Robinson, Bridget A., Dachs, Gabi U.·2018·Frontiers in Oncology

Abstract

Hypoxia-inducible transcription factors (HIFs) drive angiogenesis and cancer cell growth, contributing to an aggressive tumor phenotype. HIF-α protein levels and activity are controlled at the post-translational level by HIF hydroxylases. Hydroxylated HIF-α is recognized by the von Hippel Lindau (VHL) tumor suppressor and targeted for degradation. The HIF hydroxylases are members of the iron and 2-oxoglutarate-dependent dioxygenases, which require ascorbate as cofactor for activity. Clear cell renal carcinomas (ccRCC) harbor mutations in the VHL gene, whereas papillary RCC (pRCC) have a functional VHL. These natural occurring VHL variants in RCC enable the testing, in clinical samples, of the hypothesis that ascorbate modulates HIF-α levels through its role as a cofactor for the HIF hydroxylases. We measured ascorbate, HIF-1α and HIF-2α protein and HIF downstream targets BNIP3, CA9, cyclin D1, GLUT1 and VEGF (combined to generate the HIF pathway score) in VHL-defective ccRCC (n = 73) and VHL-proficient pRCC human tumor tissue (n = 41). HIF and ascorbate levels were increased in ccRCC and pRCC tumors compared to matched renal cortex. HIF-1 and total HIF pathway activation scores were decreased with higher ascorbate in pRCC tumors (Spearman r = -0.38, p < 0.05 and r = -0.35, p < 0.05). This was not evident for ccRCC tumors. In mechanistic studies in vitro, ascorbate influenced HIF-1 activity in VHL-proficient, but not VHL-defective ccRCC cells. Our results indicate that ccRCC, which lacks a functional VHL, does not respond to ascorbate-mediated modulation of the HIF response. This contrasts with the demonstrated association between ascorbate content and the HIF pathway observed in pRCC and other tumors with a functional VHL. The results support a role for ascorbate as a modulator of HIF activity and tumor aggression in cancer types with a functional hypoxic response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fonc.2018.00574

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Human samples for endometrial cancer, RCC, and CRC showed that tumours with the highest HIF1 activity were ascorbate-deficient.

    “Using human patient tumour samples and paired controls for endometrial cancer, renal cell carcinoma (RCC) and CRC, it was demonstrated that tumours that had the highest HIF1 activity were those deficient in ascorbate in tumours84–86.”

    From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [85]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 40 · Cited by 35

Authors
Wohlrab, C., Vissers, M. C. M., Phillips, E., Morrin, H., Robinson, B. A., & Dachs, G. U.
Affiliations
  • University of Otago (NZ)
  • Christchurch Hospital (NZ)
Corresponding author
Dachs, Gabi U.
Venue
Frontiers in Oncology
Published
2018-11-30
Volume
8
Pages
574-574
ISSN
2234-943X (ISSN-L)
OpenAlex
W2902891753
Cited by
35
References
40
Citations by year
2026: 2 · 2025: 5 · 2024: 6 · 2023: 1 · 2022: 4 · 2021: 5 · 2020: 8 · 2019: 4
FWCI
1.28
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • University of Otago
  • Cancer Society of New Zealand
  • Centre Scientifique et Technique du Bâtiment
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Renal cell carcinoma treatment
  • Health Sciences › Nursing › Nutrition and Dietetics › Vitamin C and Antioxidants Research
Keywords
vitamin C, hypoxia-inducible factor, HIF-1α, HIF-2α, von Hippel-Lindau protein, clear cell renal cell carcinoma, papillary renal cell carcinoma, tumor hypoxia, tumor aggressiveness, vascular endothelial growth factor, carbonic anhydrase IX, BNIP3, cyclin D1, GLUT1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review